Cineverse (NASDAQ: CNVS) director reports 32,413-share equity retainer grant
Rhea-AI Filing Summary
Cineverse Corp. director reports equity compensation grant
A Cineverse Corp. director reported receiving 32,413 shares of Class A common stock on December 8, 2025. This stock represents the equity portion of the director’s annual board retainer for the service year commencing October 1, 2025. The shares vest in four equal quarterly installments on December 31, 2025, March 31, 2026, June 30, 2026 and September 30, 2026, subject to the director continuing to serve on the board on each vesting date.
Following this grant, the director is shown as beneficially owning 160,361 Class A common shares directly and 4,603 shares indirectly through Grassmere Partners, LLC, where he is Chairman. He disclaims beneficial ownership of the indirectly held shares except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 32,413 | $0.00 | -- |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- Constitutes stock portion of annual retainer for the year of board service by the Reporting Person commencing October 1, 2025. Such shares vest in quarterly amounts on December 31, 2025, March 31, 2026, June 30, 2026 and September 30, 2026, so long as the Reporting Person is a director on each such date. Shares are held by Grassmere Partners, LLC, of which the Reporting Person is Chairman. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
FAQ
What did the CNVS director report in this Form 4 filing?
The director reported receiving 32,413 shares of Cineverse Corp. Class A common stock as part of his annual board retainer, with the transaction dated December 8, 2025.
Was there a cash price associated with the CNVS stock grant to the director?
The Form 4 indicates the 32,413 Class A shares were acquired at a reported price of $0, consistent with a stock-based compensation grant rather than an open-market purchase.